Currently 0 9 0 9 O
receiving 10 19 10 19 O
or 20 22 20 22 O
history 23 30 23 30 O
of 31 33 31 33 O
systemic 34 42 34 42 B-treatment
therapy 43 50 43 50 I-treatment
with 51 55 51 55 O
testosterone 56 68 56 68 B-treatment
suppressing 69 80 69 80 I-treatment
medication 81 91 81 91 I-treatment
( 92 93 92 93 O
i.e. 93 97 93 97 O
, 97 98 97 98 O
lupron 99 105 99 105 B-treatment
, 105 106 105 106 O
degarelix 107 116 107 116 B-treatment
, 116 117 116 117 O
abiraterone 118 129 118 129 B-treatment
, 129 130 129 130 O
enzalutamide 131 143 131 143 B-treatment
) 143 144 143 144 O
or 145 147 145 147 O
local 148 153 148 153 B-treatment
radiation 154 163 154 163 I-treatment
therapy 164 171 164 171 I-treatment

Gleason 0 7 172 179 B-clinical_variable
score 8 13 180 185 I-clinical_variable
= 14 15 186 187 O
8/ 16 18 188 190 B-lower_bound
> 19 20 191 192 O
8 21 22 193 194 O

Patient 0 7 195 202 O
is 8 10 203 205 O
at 11 13 206 208 O
low 14 17 209 212 O
risk 18 22 213 217 O
for 23 26 218 221 O
metastasis 27 37 222 232 B-cancer
with 38 42 233 237 O
Gleason 43 50 238 245 B-clinical_variable
score 51 56 246 251 I-clinical_variable
at 57 59 252 254 O
diagnosis 60 69 255 264 O
< 70 71 265 266 O
8 72 73 267 268 B-upper_bound

Prostate 0 8 269 277 B-cancer
carcinoma 9 18 278 287 I-cancer
patients 19 27 288 296 O
at 28 30 297 299 O
high 31 35 300 304 O
risk 36 40 305 309 O
for 41 44 310 313 O
metastasis 45 55 314 324 B-cancer

prostate 0 8 325 333 B-clinical_variable
- 8 9 333 334 I-clinical_variable
specific 9 17 334 342 I-clinical_variable
antigen 18 25 343 350 I-clinical_variable
( 26 27 351 352 I-clinical_variable
PSA 27 30 352 355 I-clinical_variable
) 30 31 355 356 I-clinical_variable
more 32 36 357 361 O
than 37 41 362 366 O
20 42 44 367 369 B-lower_bound
ng 45 47 370 372 I-lower_bound
/ 47 48 372 373 I-lower_bound
ml 48 50 373 375 I-lower_bound

